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A B S T R A C T
Purpose: Cornelia de Lange (CdLS) syndrome is characterized by multiple congenital anomalies and
mental retardation. Epilepsy is a clinical feature found in about 20% of cases, but there are no data about
its electroclinical features and long-term outcome.
Methods: we describe a clinical series of fourteen Caucasian CdLS paediatric patients who developed
epilepsy, with special reference to the long term prognosis.
Results: Epilepsy manifested between age 0.6 and 16.3 years. The majority of patients (64.3%) presented
with partial seizures and interictal EEGs mainly revealed focal epileptic paroxysms involving temporal
and parietal areas. Thirteen of 14 children became seizure-free with treatment. Valproate monotherapy
was used in eight patients (57.1%), controlling seizures in seven. Otherwise monotherapy with
topiramate, levetiracetam, carbamazepine and oxcarbazepine appeared to be effective in controlling
seizures in four cases. At the end of the follow-up (age range, 7.3–24.2 years; follow-up, 8.2  3.9 years),
thirteen patients were seizure free (three still in therapy), while in one patient seizures were not controlled.
Conclusions: Partial epilepsy is the most common type of epilepsy in CdLS patients. In the majority of
cases the prognosis of this epilepsy is favourable and therapy can be withdrawn after few years of
complete seizure control.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Cornelia de Lange syndrome (CdLS) is a multiple congenital
anomaly syndrome that is also known by the name of ‘‘Brach-
mann-de Lange’’ referring to the doctors who ﬁrst described the
syndrome.1,2 The estimated prevalence ranges from 1:45,000 to
1:62,000 as recently observed by a European working group.3
CdLS is characterized by a broad spectrum of distinctive clinical
features: facial dysmorphisms (such as arched eyebrows, broad
nasal bridge, thin upper lip and micrognatia), microcephaly, upper
limb defects, psychomotor development delay, hirsutism, small* Corresponding author at: Department of Pediatrics, University of Chieti, Via dei
Vestini 5, 66100 Chieti, Italy. Tel.: +39 0871 358020; fax: +39 0871 574831.
E-mail address: gprezioso@hotmail.it (G. Prezioso).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.01.017stature, mental retardation and behavioural disorders (Fig. 1).
Cardiac, gastrointestinal, musculoskeletal, optical, uditive and
neurosensory systems are often involved to varying degrees.
Clinical involvement ranges from mild to severe (classic) pheno-
type. In about 50% of patients three different dominant gene
mutations are detected: NIBPL (5p13), SMC1A (Xp11.22-p11.21)
and SMC3 (10q25). Initial diagnosis is usually based on clinical
features following speciﬁc diagnostic scoring systems 4 and can be
conﬁrmed by positive molecular genetic testing.
Many studies focused on the importance of neurologic ﬁndings
and reported an incidence of epilepsy in CdLS ranging from 14% to
25%, especially in the classic and more severe form of the
syndrome.4–9 However, there is little information about seizure
semiology, EEG ﬁndings and the natural course of epilepsy in CdLS
patients reported in literature and data are not homogeneous.
Therefore, the purpose of this multicenter study was to analyze thevier Ltd. All rights reserved.
Fig. 1. (A) Look at distinctive dysmorphic features like synophris (arched eyebrows), long eyelashes, broad nasal bridge, prominent philtrum with thin upper lip, widely
spaced teeth. (B) Same patient showing upper limb anomalies: disproportioned shortening of 1st metacarpal and right wrist malformation.
A. Verrotti et al. / Seizure 22 (2013) 356–359 357electroclinical aspects and the long term prognosis of patients with
epilepsy.
2. Methods
A cohort of epileptic patients with CdLS was selected in nine
neurological paediatric centres. The diagnosis of CdLS was made
following the clinical diagnostic criteria developed by the consensus
among the Clinical Advisory Board of the CdLS Foundation USA and
the scientiﬁc advisory committee of the World CdLS Federation.4
These criteria were focused on facial aspects, together with growth,
developmental and behavioural deﬁcits, correlated with ﬁndings
reported in other major system, such as musculoskeletal, neurosen-
sory, cutaneous and other major systems ﬁndings.
All patients were from non-consanguineous Caucasian parents.
Age at onset, seizure semiology, EEG features, antiepileptic drug
(AED) efﬁcacy and neuroimaging studies were evaluated. All
patients were followed for at least 5 years.Table 1
Summary of the 14 reported epileptic patients with CdLS.
Seizure semiology Brain MR
PS 9 (64.3%) Normal 
GS 3 (21.4%) Abnormal
PS!SG 1 (7.1%) Thin co
PS + GS 1 (7.1%) Cisterna
Interictal EEG Periven
Focal abnormalities 10 (71.4%)
S 5 (50%) EEG outc
SW 3 (30%) Normal 
PSW 2 (20%) Abnormal
Brain areas involved
Parieto-occipital 6 (60%) Seizure o
Fronto-temporal 1 (10%) Seizure fr
Fronto-central 1 (10%) Not contr
Centro-temporal 1 (10%)
Temporo-occipital 1 (10%)
Generalized abnormalities 4 (28.6%)
GSW 3 (75%)
Slow waves 1 (25%)
AED therapy
Monotherapy 11 (78.6%)
VPA 8 (66.7%)
LEV 1 (8.4%)
CBZ 1 (8.4%)
OXC 1 (8.4%)
Politherapy (VPA + TPM) 1 (8.4%)
VPA ! TPM 1 (7.1%)
No therapy 1 (7.1%)
PS, partial seizures; SG, secondary generalization; GS, generalized seizures; S, spike; SW
LEV, levetiracetam; CBZ, carbamazepine; OXC, oxcarbazepine; TPM, topiramate.3. Results (see Table 1)
Fourteen patients (female/male ratio = 11/3) with CdLS who
developed seizures were evaluated. The mean age at seizure onset
was 4.4  3.6 years, and the mean age at the most recent follow-up was
12.6  5.0 years. Out of fourteen patients, eleven (78.6%) suffered from
focal seizures, sometimes evolving to generalized convulsions, while
three patients (21.4%) had primary generalized tonic-clonic seizures.
Two patients (14.6%) had a positive family history of febrile seizures or
epilepsy; in addition, febrile seizures were reported in other two
patients (14.6%). Interictal EEGs detected in ten cases (71.4%) focal
anomalies: details of interictal abnormalities are reported in Table 1.
Cerebral magnetic resonance imaging (MRI) evidenced pathological
ﬁndings in three subjects (21.4%). Valproate (VPA) monotherapy was
undertaken in eight patients (57.1%), controlling seizure in seven; in
one case VPA was administered in combination with topiramate (TPM),
resulting in effective seizure control. One child who was unresponsive
to VPA remained seizure-free after TPM therapy. Monotherapy with
levetiracetam, carbamazepine or oxcarbazepine lead to remission inI
11 (78.6%)
 3 (21.4%)
rpus callosum 1 (7.1%)
 magna dilation + hypotrophy of cerebellar vermis 1 (7.1%)
tricular leukomalacia 1 (7.1%)
ome
12 (85.7%)
 2 (14.3%)
utcome
ee 13 (92.9%)
olled 1 (7.1%)
, spike-wave; PSW, polispike-wave; GSW, generalized spike-wave; VPA, valproate;
Fig. 2. Interictal EEG recording in sleep with sharp waves with slow component in left parieto-occipital areas.
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4.3  2.1 years.
At the last follow-up, thirteen patients were seizure-free: one of
these still had an abnormal EEG pattern. Only one child had both an
abnormal EEG and a negative clinical outcome at the most recent
evaluation.
4. Discussion
This study highlights for the ﬁrst time a predominant seizure
type and EEG pattern in epileptic patients with CdLS. The
majority of our patients suffered from focal seizures, while the
remaining patients showed generalized seizures or secondary
generalizations. Interictal EEG recordings showed a prevalence
of focal discharges, mainly localized in parieto-occipital region
(Fig. 2).
Although previous studies have reported an increased inci-
dence of seizures in CdLS, a speciﬁc electroclinical pattern was not
evidenced. Barr et al.6 analyzed neurologic, genetic, EEG, and
psychometric data in nineteen cases of CdLS and reported four
severely mentally retarded patients who also had seizure and twowith a questionable seizure history. A family history of seizures
was reported in four patients: of which only two actually
presented seizures. EEG ﬁndings were negative in these patients
but other four asymptomatic patients showed bisynchronous and
generalized epileptiform activity on EEG while one patient had
focal right temporal epileptiform activity. As we experienced,
photic stimulation did not activate anomalies in any of the
nineteen patients, whereas three patients with epileptiform
activity had additional sleep-activated multifocal spike discharges.
Hawley et al.7 described an interesting link between classic
phenotype, lower birth weight and seizure incidence after
assessing sixty-four patients with CdLS. Selicorni et al.11 detected
seizures in six out of thirty patients with CdLS, ﬁve with classic
type and one with mild type. Deardorff et al.8 noted an incidence of
non-speciﬁed seizure in CdLS of about 25%. Kline et al.10 evaluating
forty-nine patients affected by CdLS, described an incidence of
seizure of 26%, with a typical age of onset prior to 18 years and
well-controlled with AED monotherapy. In another study Kline
et al. included seizures in primary neurologic involvements of the
syndrome, with an incidence of 23% but without describing their
EEG pattern; they included seizures in main diagnostic criteria.
A. Verrotti et al. / Seizure 22 (2013) 356–359 359The main limitation of this study is the small sample number,
which did not allow a more detailed comparison between
endophenotypes.
This is the ﬁrst study that describes the long term follow-up of
CdLS patients with epilepsy. Our data highlight a favourable
prognosis of epilepsy, reporting a tendency to a rapid and excellent
long-term response to AED therapy, despite one case of
spontaneous remission. In addition, the recurrence rate after
discontinuation was low: one patient out of fourteen (7,1%)
suffered recurrent seizures. Overall, AED common approach, and
especially VPA monotherapy, seems effective in controlling
seizures of patients with CdLS. Moreover, our experience suggests
that frequently AED therapy can be withdrawn after few years of
seizure-free follow-up. Although we did not observe any correla-
tion between MRI, seizures and EEG abnormalities, a remarkable
correlation between EEG features and clinical expressions was
found: seizure remission was followed by EEG normalization in
most of the cases. The predominant clinical EEG aspects of our
sample could ﬁll the criteria of benign occipital epilepsy, even
though the number of our patients is small. Recently12 it has been
proposed the hypothesis of the existence of the so-called System
Epilepsies. The hypothesis claims that System Epilepsies are the
result of the enduring propensity to generate seizures of different
brain areas that, alone, are unable to create a speciﬁc electroclinical
phenotype and go beyond the dichotomy between focal and
generalized epilepsy. If neurophysiologic studies in CdLS patients
add precise information about the structures and functions of the
neural network involved in epilepsy of these patients, it could be
conﬁrmed that this epilepsy can be included in the possible
prototypes of System Epilepsy.
5. Conclusions
In conclusion, our clinical series suggests that partial seizures
and focal anomalies mainly on parieto-occipital areas are commonfeatures in CdLS patients with epilepsy. Electroclinical outcome of
this type of epilepsy is generally favourable, with a good response
to monotherapy.
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